{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06382142\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T02:42:09.345Z","note":"Automated from all 16 indexed sources (Feb 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":16,"text":"- Whether results will be confirmed in a global population\n- Whether iza-bren has a role in earlier treatment settings\n- Whether hematologic toxicity is manageable\n\nAlso discussed: EGFR-HER3 targeting beyond TROP2."},"drugs_tested":[["izalontamab brengitecan (BL-B01D1)"]],"indication":"unresectable locally advanced or metastatic triple-negative breast cancer","name":"PANKU-Breast02","nct_id":"NCT06382142","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=panku-breast02-nct06382142. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","label":"BL-B01D1","type":"EXPERIMENTAL"},{"description":"Participants receive Eribulin or Vinorelbine or Gemcitabine or Capecitabine in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","label":"Eribulin or Vinorelbine or Gemcitabine or Capecitabine","type":"EXPERIMENTAL"}],"collaborators":["Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Triple-Negative Breast Cancer"],"enrollment":{"count":418,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"BL-B01D1","otherNames":["iza-bren","izalontamab brengitecan","BMS-986507"],"type":"DRUG"},{"name":"Eribulin","otherNames":[],"type":"DRUG"},{"name":"Vinorelbine","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-23","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","official_title":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"Up to approximately 24 months"},{"measure":"Overall survival (OS)","timeFrame":"Up to approximately 24 months"}],"references":[],"start_date":{"date":"2024-06-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)","url":"https://clinicaltrials.gov/study/NCT06382142"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/panku-breast02-nct06382142"}